NR: Biomarker Change and Health Benefit
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

Nicotinamide riboside, or NR, is another precursor in NAD+ metabolism. It is distinct from NMN and from directly administering NAD+ itself. A randomized crossover trial in healthy middle-aged and older adults compared NR with placebo over two six-week periods. Researchers assessed tolerability and NAD+ metabolism. NR increased NAD+ in blood cells in this study. That is evidence of a biological response, not direct proof of longer life or better memory. Exploratory cardiovascular findings need further testing. Small, short trials cannot establish broad anti-aging benefits or fully characterize uncommon risks from long-term use.

END CARD
Educational draft. Not medical advice. Sources and limitations accompany this film.

SOURCES
[1] Martens et al. (2018): Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
https://pmc.ncbi.nlm.nih.gov/articles/PMC5876407/
Primary randomized placebo-controlled crossover human trial

EVIDENCE LIMITATIONS
NAD+ in a sampled blood-cell compartment does not demonstrate benefit in every tissue.
The study was not designed to establish longer life, memory improvement or prevention of major disease.
Exploratory cardiovascular findings should not be presented as established clinical benefit.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
Nicotinamide Riboside: Biomarker Change Versus Health Benefit